PURPOSE: The accurate selection of patients who are most likely to benefit from neoadjuvant chemotherapy is an important challenge in oncology. Serum AGR has been found to be associated with oncological outcomes in various malignancies. We assessed the association of pre-therapy serum albumin-to-globulin ratio (AGR) with pathologic response and oncological outcomes in patients treated with neoadjuvant platin-based chemotherapy followed by radical nephroureterectomy (RNU) for clinically non-metastatic UTUC. METHODS: We retrospectively included all clinically non-metastatic patients from a multicentric database who had neoadjuvant platin-based chemotherapy and RNU for UTUC. After assessing the pretreatment AGR cut-off value, we found 1.42 to have the maximum Youden index value. The overall population was therefore divided into two AGR groups using this cut-off (low, < 1.42 vs high, ≥ 1.42). A logistic regression was performed to measure the association with pathologic response after NAC. Univariable and multivariable Cox regression analyses tested the association of AGR with OS and RFS. RESULTS: Of 172 patients, 58 (34%) patients had an AGR < 1.42. Median follow-up was 26 (IQR 11-56) months. In logistic regression, low AGR was not associated with pathologic response. On univariable analyses, pre-therapy serum AGR was neither associated with OS HR 1.15 (95% CI 0.77-1.74; p = 0.47) nor RFS HR 1.48 (95% CI 0.98-1.22; p = 0.06). These results remained true regardless of the response to NAC. CONCLUSION: Pre-therapy low serum AGR before NAC followed by RNU for clinically high-risk UTUC was not associated with pathological response or long-term oncological outcomes. Biomarkers that can complement clinical factors in UTUC are needed as clinical staging and risk stratification are still suboptimal leading to both over and under treatment despite the availability of effective therapies.

Cancer Prognostics and Health Outcomes Unit University of Montreal Health Center Montreal Canada

Department of Special Surgery Jordan University Hospital The University of Jordan Amman Jordan

Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology Comprehensive Cancer Center Vienna General Hospital Medical University of Vienna Währinger Gürtel 18 20 1090 Vienna Austria

Department of Urology Kantonsspital Winterthur Winterthur Switzerland

Department of Urology King Fahad Specialist Hospital Ad Dammām Saudi Arabia

Department of Urology The Jikei University School of Medicine Tokyo Japan

Department of Urology The Netherlands Cancer Institute Antoni Van Leeuwenhoek Hospital Amsterdam The Netherlands

Department of Urology University Hospital Frankfurt Frankfurt Germany

Department of Urology University Hospital of Tours Tours France

Department of Urology University Hospitals Leuven Leuven Belgium

Department of Urology University of Texas Southwestern Medical Center Dallas TX USA

Department of Urology Urological Research Institute Vita Salute University San Raffaele Scientific Institute Milan Italy

Department of Urology Weill Cornell Medical College New York NY USA

Division of Urology Department of Special Surgery Jordan University Hospital The University of Jordan Amman Jordan

European Association of Urology Research Foundation Arnhem The Netherlands

Karl Landsteiner Institute of Urology and Andrology Vienna Austria

000      

00000naa a2200000 a 4500

001      

bmc22012385

003      

CZ-PrNML

005      

20220506130215.0

007      

ta

008      

220425s2021 gw f 000 0|eng||

009      

AR

024    7_

$a 10.1007/s00345-020-03479-3 $2 doi

035    __

$a (PubMed)33067726

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a gw

100    1_

$a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, University Hospital of Tours, Tours, France $1 https://orcid.org/0000000277688558

245    10

$a Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma / $c B. Pradere, D. D'Andrea, VM. Schuettfort, B. Foerster, F. Quhal, K. Mori, M. Abufaraj, V. Margulis, M. Deuker, A. Briganti, T. Muilwijk, K. Hendricksen, Y. Lotan, P. Karakiewic, S. F Shariat, UTUC collaboration

520    9_

$a PURPOSE: The accurate selection of patients who are most likely to benefit from neoadjuvant chemotherapy is an important challenge in oncology. Serum AGR has been found to be associated with oncological outcomes in various malignancies. We assessed the association of pre-therapy serum albumin-to-globulin ratio (AGR) with pathologic response and oncological outcomes in patients treated with neoadjuvant platin-based chemotherapy followed by radical nephroureterectomy (RNU) for clinically non-metastatic UTUC. METHODS: We retrospectively included all clinically non-metastatic patients from a multicentric database who had neoadjuvant platin-based chemotherapy and RNU for UTUC. After assessing the pretreatment AGR cut-off value, we found 1.42 to have the maximum Youden index value. The overall population was therefore divided into two AGR groups using this cut-off (low, < 1.42 vs high, ≥ 1.42). A logistic regression was performed to measure the association with pathologic response after NAC. Univariable and multivariable Cox regression analyses tested the association of AGR with OS and RFS. RESULTS: Of 172 patients, 58 (34%) patients had an AGR < 1.42. Median follow-up was 26 (IQR 11-56) months. In logistic regression, low AGR was not associated with pathologic response. On univariable analyses, pre-therapy serum AGR was neither associated with OS HR 1.15 (95% CI 0.77-1.74; p = 0.47) nor RFS HR 1.48 (95% CI 0.98-1.22; p = 0.06). These results remained true regardless of the response to NAC. CONCLUSION: Pre-therapy low serum AGR before NAC followed by RNU for clinically high-risk UTUC was not associated with pathological response or long-term oncological outcomes. Biomarkers that can complement clinical factors in UTUC are needed as clinical staging and risk stratification are still suboptimal leading to both over and under treatment despite the availability of effective therapies.

650    _2

$a senioři $7 D000368

650    _2

$a karcinom z přechodných buněk $x krev $x terapie $7 D002295

650    _2

$a globuliny $x analýza $7 D005916

650    _2

$a lidé $7 D006801

650    _2

$a nádory ledvin $x krev $x terapie $7 D007680

650    _2

$a lidé středního věku $7 D008875

650    _2

$a neoadjuvantní terapie $7 D020360

650    _2

$a mnohočetné primární nádory $x krev $x terapie $7 D009378

650    12

$a nefroureterektomie $7 D000074682

650    _2

$a retrospektivní studie $7 D012189

650    _2

$a sérový albumin $x analýza $7 D012709

650    _2

$a výsledek terapie $7 D016896

650    _2

$a nádory močovodu $x krev $x terapie $7 D014516

655    _2

$a časopisecké články $7 D016428

700    1_

$a D'Andrea, David $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria

700    1_

$a Schuettfort, Victor M $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria

700    1_

$a Foerster, Beat $u Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland

700    1_

$a Quhal, Fahad $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, King Fahad Specialist Hospital, Ad Dammām, Saudi Arabia

700    1_

$a Mori, Keiichiro $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan

700    1_

$a Abufaraj, Mohammad $u Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan

700    1_

$a Margulis, Vitaly $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA

700    1_

$a Deuker, Marine $u Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Canada $u Department of Urology, University Hospital Frankfurt, Frankfurt, Germany

700    1_

$a Briganti, Alberto $u Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy

700    1_

$a Muilwijk, Tim $u Department of Urology, University Hospitals Leuven, Leuven, Belgium

700    1_

$a Hendricksen, Kees $u Department of Urology, The Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, The Netherlands

700    1_

$a Lotan, Yair $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA

700    1_

$a Karakiewic, Pierre $u Department of Urology, University Hospital Frankfurt, Frankfurt, Germany

700    1_

$a F Shariat, Shahrokh $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Weill Cornell Medical College, New York, NY, USA. shahrokh.shariat@meduniwien.ac.at $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. shahrokh.shariat@meduniwien.ac.at $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria. shahrokh.shariat@meduniwien.ac.at $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan. shahrokh.shariat@meduniwien.ac.at $u European Association of Urology Research Foundation, Arnhem, The Netherlands. shahrokh.shariat@meduniwien.ac.at

710    2_

$a UTUC collaboration

773    0_

$w MED00004739 $t World journal of urology $x 1433-8726 $g Roč. 39, č. 7 (2021), s. 2567-2577

856    41

$u https://pubmed.ncbi.nlm.nih.gov/33067726 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20220425 $b ABA008

991    __

$a 20220506130208 $b ABA008

999    __

$a ok $b bmc $g 1789820 $s 1163586

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2021 $b 39 $c 7 $d 2567-2577 $e 20201016 $i 1433-8726 $m World journal of urology $n World J Urol $x MED00004739

LZP    __

$a Pubmed-20220425